According to data from eToro, leading the list was telehealth platform, Hims & Hers Health, which surged 85 per cent in ...

Hims & Hers Health, Inc. (HIMS) announced on Wednesday that it will expand to Canada next year with its weight loss program, ...

U.S. telehealth platform looks to take advantage of Ozempic patent expiring in January, while four manufacturers filed for ...

Hims and Hers announced this morning that it will begin offering compounded semaglutide (generic Ozempic or Wegovy) for $199 ...

U.S. telehealth upstart Hims & Hers Health, Inc. is planning to enter the Canadian market with an eye to selling generic ...

Seeking Alpha's daily roundup of remarks and statements that could impact markets, sectors or individual stocks. Read more ...

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.1% in the morning session after the company announced ...

Hims & Hers announced plans to expand its weight loss program to Canada in 2026 in connection with the availability of generic semaglutide anywhere in the world.

The Hims & Hers wellness platform announced Wednesday it will soon offer a generic version of the weight loss drug semaglutide in Canada as Novo Nordisk's patent on its branded version, known as ...

The move follows a dramatic breakup in June between Hims & Hers and Danish drug maker Novo Nordisk, which makes the brand name weight loss drug Wegovy. Novo Nordisk accused the Hims & Hers of ...

Hims & Hers Health plans to expand into Canada, timing it with the new availability of the generic weight loss medication on the market for the first time.